Last $2.55 USD
Change Today +0.07 / 2.82%
Volume 47.1K
DARA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

dara biosciences inc (DARA) Snapshot

Open
$2.47
Previous Close
$2.48
Day High
$2.61
Day Low
$2.47
52 Week High
01/22/14 - $4.40
52 Week Low
11/12/13 - $2.25
Market Cap
21.4M
Average Volume 10 Days
95.6K
EPS TTM
$-1.95
Shares Outstanding
8.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DARA BIOSCIENCES INC (DARA)

Related News

No related news articles were found.

dara biosciences inc (DARA) Related Businessweek News

No Related Businessweek News Found

dara biosciences inc (DARA) Details

DARA BioSciences, Inc., a development stage biopharmaceutical company, develops and commercializes oncology treatment and supportive care pharmaceutical products in the United States. It offers Soltamox for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The company’s oncology supportive care pharmaceutical products comprise Gelclair, an oral gel for the treatment of oral mucositis; and Bionect for the management of irritation of the skin, as well as first and second degree burns. Its clinical development programs include KRN5500, a novel, non-narcotic/non-opioid intravenous product for the treatment of cancer patients with painful chronic chemotherapy induced peripheral neuropathy, which has completed Phase 2a development; and DB959, a drug candidate for the treatment of type 2 diabetes and dyslipidemia. DARA BioSciences, Inc. was incorporated in 2002 and is headquartered in Raleigh, North Carolina.

13 Employees
Last Reported Date: 02/4/14
Founded in 2002

dara biosciences inc (DARA) Top Compensated Officers

Chief Executive Officer, Chief Medical Office...
Total Annual Compensation: $325.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $275.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2013.

dara biosciences inc (DARA) Key Developments

DARA BioSciences, Inc. Signs Medicare Part D Prescription Drug Program Reimbursement Agreement with Comprehensive Health Management, Inc

DARA BioSciences, Inc. announced that the company signed a Medicare Part D Prescription Drug Program Reimbursement Agreement with Comprehensive Health Management, Inc. (CHMI) providing formulary status for the WellCare(R) Group of Companies for Soltamox(R) (tamoxifen citrate) oral solution, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer. Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen. DARA holds exclusive U.S. marketing rights to Soltamox, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer. Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen.

DARA BioSciences Regains Compliance With NASDAQ Bid Price Requirement

DARA BioSciences, Inc. announced that it has received notice from the NASDAQ Listing Qualifications Staff that it has regained compliance with the minimum $1.00 bid price per share requirement. The previously disclosed NASDAQ delisting matter related to the Company's bid price compliance is now closed.

DARA BioSciences, Inc Presents at 26th Annual ROTH Conference, Mar-12-2014 10:00 AM

DARA BioSciences, Inc Presents at 26th Annual ROTH Conference, Mar-12-2014 10:00 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: David J. Drutz, Chief Executive Officer, Chief Medical Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DARA:US $2.55 USD +0.07

DARA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DARA.
View Industry Companies
 

Industry Analysis

DARA

Industry Average

Valuation DARA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.0x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DARA BIOSCIENCES INC, please visit www.darabiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.